BUET 1 mg ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
98Eosinophilic gastrointestinal disease1

98. Eosinophilic gastrointestinal disease


Clinical trials : 172 Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001485-99-IT
(EUCTR)
29/09/201720/01/2021Double-blind (neither physician nor patient knows of the actual treatment which can with or without active substance), randomized (patient will be allocated to a certain treatment group by chance), phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets in comparison with placebo formaintenance of clinico-pathological remission in adult patients with eosinophilic esophagitisDouble-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinicopathological remission in adult patients with eosinophilic esophagitis - Maintenance of remission with budesonide effervescent tabl. vs. placebo in eosinophilic esophagitis Maintenance of remission in eosinophilic esophagitis
MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Compressa effervescente 1 mg di budesonide per uso orodispersibile
Product Code: BUET 1 mg
INN or Proposed INN: BUDESONIDE
Product Name: Compressa effervescente 0,5 mg di budesonide per uso orodispersibile
Product Code: BUET 0.5 mg
INN or Proposed INN: BUDESONIDE
DR. FALK PHARMA GMBHNULLNot RecruitingFemale: yes
Male: yes
204Phase 3Belgium;Denmark;Netherlands;Germany;United Kingdom;Switzerland;Italy;Eswatini;Spain